Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Neutral 62.6%

Neg 0% Neu 62.6% Pos 0%

Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $60.